Precision gene therapy for liver disorders increases number of correctly repaired cells
Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Reprogramming compromised immune cells to fight cancer
Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...
sicklecellanemianews1d
SCD patients can access Casgevy via England’s public health system
Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...
The EMBO Journal2d
A CRISPR-Cas9 screen reveals genetic determinants of the cellular response to decitabine
A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...
sicklecellanemianews6d
SCD gene-editing therapy Casgevy now being offered at CHLA
With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.